Market capitalization | $4.43b |
Enterprise Value | $3.58b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2,817.28 |
P/S ratio (TTM) P/S ratio | 3,484.43 |
P/B ratio (TTM) P/B ratio | 3.19 |
Revenue growth (TTM) Revenue growth | -99.63% |
Revenue (TTM) Revenue | $1.27m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
15 Analysts have issued a Denali Therapeutics Inc. forecast:
15 Analysts have issued a Denali Therapeutics Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1.27 1.27 |
100%
100%
|
|
Gross Profit | -7.23 -7.23 |
102%
102%
|
|
EBITDA | -487 -487 |
229%
229%
|
EBIT (Operating Income) EBIT | -495 -495 |
204%
204%
|
Net Profit | -420 -420 |
227%
227%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Ryan Watts |
Employees | 445 |
Founded | 2013 |
Website | www.denalitherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.